Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin

Péter Dombi, Árpád Illés, J. Demeter, Lajos Homor, Zsofia Simon, Eva Karadi, Miklos Udvardy, Miklos Egyed

Research output: Article

6 Citations (Scopus)

Abstract

Objective: To evaluate the reduction in thrombotic events (TE) in patients with essential thrombocythaemia (ET) treated with anagrelide versus hydroxyurea + aspirin (HU + ASA). Methods: A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TEs in anagrelide-treated patients (n = 139) were compared with HU + ASA-treated patients (n = 141). Results: Patients were followed up for (median) 6 yr. TEs were reported in significantly fewer anagrelide-treated patients versus HU + ASA (15.1% versus 49.6%; P < 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the HU + ASA group (P < 0.001). While median age at diagnosis was older and length of follow-up shorter in the HU + ASA group (P < 0.05), this did not influence TE incidence; medication and TE before diagnosis only influenced TE incidence. Conclusions: Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TEs versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.

Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalEuropean Journal of Haematology
Volume98
Issue number2
DOIs
Publication statusPublished - febr. 1 2017

Fingerprint

Essential Thrombocythemia
Hydroxyurea
Aspirin
Registries
anagrelide
Incidence

ASJC Scopus subject areas

  • Hematology

Cite this

Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. / Dombi, Péter; Illés, Árpád; Demeter, J.; Homor, Lajos; Simon, Zsofia; Karadi, Eva; Udvardy, Miklos; Egyed, Miklos.

In: European Journal of Haematology, Vol. 98, No. 2, 01.02.2017, p. 106-111.

Research output: Article

Dombi, P, Illés, Á, Demeter, J, Homor, L, Simon, Z, Karadi, E, Udvardy, M & Egyed, M 2017, 'Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin', European Journal of Haematology, vol. 98, no. 2, pp. 106-111. https://doi.org/10.1111/ejh.12806
Dombi, Péter ; Illés, Árpád ; Demeter, J. ; Homor, Lajos ; Simon, Zsofia ; Karadi, Eva ; Udvardy, Miklos ; Egyed, Miklos. / Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. In: European Journal of Haematology. 2017 ; Vol. 98, No. 2. pp. 106-111.
@article{741e4f88ee4549c8a03a533da69f0d79,
title = "Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin",
abstract = "Objective: To evaluate the reduction in thrombotic events (TE) in patients with essential thrombocythaemia (ET) treated with anagrelide versus hydroxyurea + aspirin (HU + ASA). Methods: A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TEs in anagrelide-treated patients (n = 139) were compared with HU + ASA-treated patients (n = 141). Results: Patients were followed up for (median) 6 yr. TEs were reported in significantly fewer anagrelide-treated patients versus HU + ASA (15.1{\%} versus 49.6{\%}; P < 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the HU + ASA group (P < 0.001). While median age at diagnosis was older and length of follow-up shorter in the HU + ASA group (P < 0.05), this did not influence TE incidence; medication and TE before diagnosis only influenced TE incidence. Conclusions: Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TEs versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.",
keywords = "anagrelide, essential thrombocythaemia, hydroxyurea + aspirin, registry, risk factors, thrombosis",
author = "P{\'e}ter Dombi and {\'A}rp{\'a}d Ill{\'e}s and J. Demeter and Lajos Homor and Zsofia Simon and Eva Karadi and Miklos Udvardy and Miklos Egyed",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/ejh.12806",
language = "English",
volume = "98",
pages = "106--111",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin

AU - Dombi, Péter

AU - Illés, Árpád

AU - Demeter, J.

AU - Homor, Lajos

AU - Simon, Zsofia

AU - Karadi, Eva

AU - Udvardy, Miklos

AU - Egyed, Miklos

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Objective: To evaluate the reduction in thrombotic events (TE) in patients with essential thrombocythaemia (ET) treated with anagrelide versus hydroxyurea + aspirin (HU + ASA). Methods: A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TEs in anagrelide-treated patients (n = 139) were compared with HU + ASA-treated patients (n = 141). Results: Patients were followed up for (median) 6 yr. TEs were reported in significantly fewer anagrelide-treated patients versus HU + ASA (15.1% versus 49.6%; P < 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the HU + ASA group (P < 0.001). While median age at diagnosis was older and length of follow-up shorter in the HU + ASA group (P < 0.05), this did not influence TE incidence; medication and TE before diagnosis only influenced TE incidence. Conclusions: Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TEs versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.

AB - Objective: To evaluate the reduction in thrombotic events (TE) in patients with essential thrombocythaemia (ET) treated with anagrelide versus hydroxyurea + aspirin (HU + ASA). Methods: A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk factors were stratified according to Landolfi criteria. Through questionnaire completion, clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry on patients with myeloproliferative neoplasms. Based on ET registry data, TEs in anagrelide-treated patients (n = 139) were compared with HU + ASA-treated patients (n = 141). Results: Patients were followed up for (median) 6 yr. TEs were reported in significantly fewer anagrelide-treated patients versus HU + ASA (15.1% versus 49.6%; P < 0.001). Numbers of major arterial and major venous events were similar between the groups, although there were over fivefold more minor arterial and minor venous events in the HU + ASA group (P < 0.001). While median age at diagnosis was older and length of follow-up shorter in the HU + ASA group (P < 0.05), this did not influence TE incidence; medication and TE before diagnosis only influenced TE incidence. Conclusions: Anagrelide significantly decreased the number of patients experiencing minor arterial and minor venous TEs versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly increased if the patient had TE before diagnosis.

KW - anagrelide

KW - essential thrombocythaemia

KW - hydroxyurea + aspirin

KW - registry

KW - risk factors

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84992499034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992499034&partnerID=8YFLogxK

U2 - 10.1111/ejh.12806

DO - 10.1111/ejh.12806

M3 - Article

VL - 98

SP - 106

EP - 111

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -